Skip to main content
Premium Trial:

Request an Annual Quote

If You Can't Beat Them ...

Wall Street Journal reports that Carl Icahn won a seat on Biogen Idec's board of directors, with the results of a possible second seat still up in the air, according to the article. "Icahn, who owns about 5.6% of Biogen and favors its break-up or sale, has claimed his candidates won two seats on Biogen's 13-member board, after a months-long proxy fight that ended Wednesday with a raucous shareholder meeting in Cambridge, Mass.," the article says. "After almost two years as an outsider and critic of Biogen, Mr. Icahn now has a toehold on its board and access to internal discussions at the company."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.